NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Feb 18, 2026–
Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This new facility will further expand the Company’s U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218830893/en/…